Newron: Stock plummets as schizophrenia drug trial delayed

Newron Pharmaceuticals SpA

28/05/2019 08:18

** Swiss-listed drugmaker Newron  NWRN.S  drops 16% and is
set for the worst day in over 3 years
    ** Newron must delay a trial of its prospective
schizophrenia medicine evenamide  urn:newsml:reuters.com:*:nL8N2340KB
    ** The U.S. FDA raised concerns about central nervous system
events that have emerged in rats and dogs
    ** The company said in March it Phase III development
program for evenamide was on track and planned to start in
Q2/2019

 ((daria.kowalewska@tr.com))